These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17100373)

  • 1. Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3.
    Kiertiburanakul S; Sungkanuparph S; Rattanasiri S; Manosuthi W; Vibhagool A; Thakkinstian A
    J Med Assoc Thai; 2006 Sep; 89(9):1381-7. PubMed ID: 17100373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
    Maggiolo F; Migliorino M; Maserati R; Pan A; Rizzi M; Provettoni G; Rizzi L; Suter F;
    Antivir Ther; 2001 Dec; 6(4):249-53. PubMed ID: 11878406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
    HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
    Waters L; Stebbing J; Jones R; Michailidis C; Sawleshwarkar S; Mandalia S; Bower M; Nelson M; Gazzard B
    J Antimicrob Chemother; 2004 Aug; 54(2):503-7. PubMed ID: 15201230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF;
    J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability.
    Sungkanuparph S; Kiertiburanakul S; Manosuthi W; Kiatatchasai W; Vibhagool A
    Int J STD AIDS; 2005 Mar; 16(3):243-6. PubMed ID: 15829026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
    Elion R; Green L; Cohen C; Green S; Baird I; Schrader S; Ward D
    Antivir Ther; 1999; 4 Suppl 3():89-91. PubMed ID: 16021878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.